LHLuke H. Hoeppner

Luke H. Hoeppner

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Luke H. Hoeppner has a total of 191 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Loss of miRNA-153 promotes EndMT and compromises lung vascular integrity

    by Ibrahim Elmadbouh, Zhunran Zhong, Li Wang, Stembile Chikoore, Benney Endoni, Aaditya Sah, Michael Thompson, Luke H Hoeppner, Y S Prakash, Jason X -J Yuan, et al.

    Endothelial-to-mesenchymal transition (EndMT) is a biological process through which lung vascular endothelial cells (ECs) transdifferentiate into mesenchymal-like cells. EndMT has recently been implicated in the development and progression of pulmonary vascular remodeling in pulmonary hypertension (PH); however, its underlying regulatory mechanisms remain incompletely understood. MicroRNAs (miRNAs) are key post-transcriptional regulators of EC gene expression and cellular responses to various stimuli. Notably, microRNA-153 (miR-153) has been shown to directly target SNAI1 to modulate epithelial-to-mesenchymal transition (EMT), a process closely related to EndMT and extensively studied in cancer. Whether miR-153 also participates in EndMT regulation, however, remains unknown. In this study, we demonstrate that 72-hour hypoxic exposure induces SNAI1-mediated EndMT in human lung vascular ECs. Hypoxia also increased cell proliferation and disrupted intercellular junctions, leading to enhanced endothelial permeability. Reduced miR-153 expression was observed in both hypoxia- and TGF-β1-induced EndMT, as well as in ECs isolated from PH patients exhibiting an EndMT phenotype. Similar to hypoxia, TGF-β1 promoted EC permeability. Loss of miR-153 enhanced SNAI1-mediated EndMT, endothelial survival, and permeability under normoxic conditions, whereas miR-153 overexpression attenuated EndMT induced by hypoxia or TGF-β1. However, miR-153 restoration did not completely restore endothelial barrier integrity disrupted by these stimuli. In vitro findings were validated in experimental PH model. In conclusion, miR-153 serves as a critical regulator of EndMT, maintaining endothelial identity and barrier function. Therapeutic delivery of miR-153 may therefore represent a novel strategy to inhibit EndMT and attenuate pulmonary vascular remodeling in PH.

  • Open Access

    Tumor-specific lncRNA IGF1R-AS1 trans-regulates chromatin interactions associated with oncogenic MYC signaling

    by Yongyong Yang, Ting-You Wang, Joshua Fry, Yingming Li, Qingshu Meng, Qingxiang Guo, Nathan E. Patchen, Kyle H. White, Abhirami Ramakrishnan, Yanan Ren, et al.

    LncRNAs have emerged as pivotal regulators in the development and progression of various human cancers. However, understanding the precise mechanisms by which lncRNAs influence cancer progression remains a substantial challenge, largely due to their cell type- and tissue-specific expression patterns and the lack of well-defined functional domains or motifs. In this study, we investigate the complex interplay between super-enhancers and lncRNAs through a comprehensive analysis of lncRNA expression in a cohort of metastatic castration-resistant prostate cancer patients. Our analysis identifies 1344 lncRNAs, among which an antisense lncRNA in the IGF1R locus named IGF1R-AS1 displayed the strongest super-enhancer association. Through pan-cancer transcriptome analysis, we find that IGF1R-AS1 is specifically transcribed in tumor specimens and is overexpressed in prostate and lung cancers. Notably, we reveal a non-canonical trans -acting role for IGF1R-AS1 whereby it interacts with chromatin remodeling complexes and architectural proteins to facilitate long-range chromatin looping between distal MYC enhancers and its promoter, leading to MYC overexpression and enhanced tumorigenicity. Collectively, our findings elucidate a mechanism by which a tumor-specific trans -acting lncRNA modulates oncogenic MYC expression through long-range chromatin interactions, suggesting IGF1R-AS1 may play an important role in the pathogenesis of MYC-driven malignancies.


  • Open Access

    Primary cilia promote resistance to EGFR tyrosine kinase inhibitor, osimertinib, in non–small cell lung cancer

    by Li Wang, Anuradha Pandit, Sk. Kayum Alam, Rhiannon Skauge, Sergio A. Gradilone, Luke H. Hoeppner

    Patients with advanced non–small cell lung cancer (NSCLC) and mutations in epidermal growth factor receptor (EGFR) benefit from EGFR tyrosine kinase inhibitors (TKIs). Osimertinib, a third-generation EGFR TKI, is standard first-line therapy for EGFR-mutated NSCLC, but most patients develop resistance to it. Here, we demonstrate that increased formation of primary cilia, microtubule-based sensory organelles, is associated with osimertinib-refractory NSCLC progression. EGFR-mutated, osimertinib-resistant human NSCLC cells had increased cilia formation and acetylation of α-tubulin and reduced histone deacetylase 6 (HDAC6) activity compared to their osimertinib-sensitive counterparts. HDAC6 inhibition increases cilia formation in osimertinib-sensitive NSCLC cells, and overexpression of exogenous HDAC6 sensitized osimertinib-resistant NSCLC cells to osimertinib’s anti-proliferative effects. Because intraflagellar transport (IFT) proteins are essential for primary cilium formation and function, we knocked down IFT88 in osimertinib-resistant NSCLC cells, which reversed osimertinib resistance in orthotopic and subcutaneous mouse models of lung cancer. Mechanistically, increased sodium influx during osimertinib-induced inhibition of EGFR signalling promotes cilia formation through sustained HDAC6 inactivity and greater α-tubulin acetylation. Inhibition of sodium influx with dibutyryl-cAMP decreased cilium formation, increased sensitivity to osimertinib, and reduced tumor progression in mice bearing osimertinib-resistant lung tumors. Collectively, our findings suggest that enhanced primary cilium formation mediates EGFR TKI resistance and that targeted inhibition of ciliogenesis may prevent or overcome osimertinib resistance.

  • Open Access

    Dopamine D2 receptor agonists abrogate neuroendocrine tumour angiogenesis to inhibit chemotherapy-refractory small cell lung cancer progression

    by Sk. Kayum Alam, Anuradha Pandit, Li Wang, Seyedeh Sahar Mortazavi Farsani, Britteny A. Thiele, Parvathy Manoj, Marie Christine Aubry, Vivek Verma, Charles M. Rudin, Ying-Chun Lo, et al.

    Small cell lung cancer (SCLC) is difficult to treat due to its aggressiveness, early metastasis, and rapid development of resistance to chemotherapeutic agents. Here, we show that treatment with a dopamine D2 receptor (D2R) agonist reduces tumour angiogenesis in multiple in vivo xenograft models of human SCLC, thereby reducing SCLC progression. An FDA-approved D2R agonist, cabergoline, also sensitized chemotherapy-resistant SCLC tumours to cisplatin and etoposide in patient-derived xenograft models of acquired chemoresistance in mice. Ex vivo, D2R agonist treatment decreased tumour angiogenesis through increased apoptosis of tumour-associated endothelial cells, creating a less favourable tumour microenvironment that limited cancer cell proliferation. In paired SCLC patient-derived specimens, D2R was expressed by tumour-associated endothelial cells obtained before treatment, but D2R was downregulated in SCLC tumours that had acquired chemoresistance. D2R agonist treatment of chemotherapy-resistant specimens restored expression of D2R. Activation of dopamine signalling is thus a new strategy for inhibiting angiogenesis in SCLC and potentially for combatting chemotherapy-refractory SCLC progression.


  • Open Access

    The repurposed STAT3 inhibitor pyrimethamine controls mycobacterial infection-induced vascular permeability and mycobacterial burden

    by Darryl Jy Han, Xiangyu Sui, Ria Sorayah, Luke H Hoeppner, Stefan H Oehlers

    Infection-induced vascular pathologies are a side effect of the immune response to contact with a range of pathogens. Mycobacteria, including Mycobacterium tuberculosis, are particularly adept at co-opting vascular leakiness as a survival mechanism to shape the host immune response and impede the delivery of antibiotics to sites of infection. Here using the zebrafish-Mycobacterium marinum infection model, we confirm a critical role for Signal transducer and activator of transcription 3 (STAT3) in mediating infection-induced vascular permeability, and demonstrate the ability of FDA-approved drugs atovaquone and pyrimethamine to restore vascular barrier function without compromising immune control of mycobacterial infection. Additionally, we find an antibiotic effect of pyrimethamine against Mycobacterium marinum via inhibition of bacterial dihydrofolate reductase. Together our findings suggest pyrimethamine could be used as adjunctive therapy against mycobacterial infection.

  • Open Access

    Dopamine D 2 receptor agonists abrogate neuroendocrine tumour angiogenesis to inhibit chemotherapy-refractory small cell lung cancer progression

    by Sk. Kayum Alam, Anuradha Pandit, Li Wang, Britteny A. Thiele, Parvathy Manoj, Marie Christine Aubry, Charles M. Rudin, Ying-Chun Lo, Luke H. Hoeppner

    Small cell lung cancer (SCLC) is difficult to treat due to its aggressiveness, early metastasis, and rapid development of resistance to chemotherapeutic agents. Here, we show that treatment with a dopamine D 2 receptor (D 2 R) agonist reduces tumour angiogenesis in multiple in vivo xenograft models of human SCLC, thereby reducing SCLC progression. An FDA-approved D 2 R agonist, cabergoline, also sensitized chemoresistant SCLC tumours to cisplatin and etoposide in patient-derived xenograft models of acquired chemoresistance in mice. Ex vivo , D 2 R agonist treatment decreased tumour angiogenesis through increased apoptosis of tumour-associated endothelial cells, creating a less favourable tumour microenvironment that limited cancer cell proliferation. In paired SCLC patient-derived specimens, D 2 R was expressed by tumour-associated endothelial cells obtained before treatment, but D 2 R was downregulated in SCLC tumours that had acquired chemoresistance. D 2 R agonist treatment of chemotherapy-resistant specimens restored expression of D 2 R. Activation of dopamine signalling is thus a new strategy for inhibiting angiogenesis in SCLC and potentially for combatting chemotherapy-refractory SCLC progression.

  • Open Access

    Radiation dermatitis in the hairless mouse model mimics human radiation dermatitis

    by Jessica Lawrence, Davis Seelig, Kimberly Demos-Davies, Clara Ferreira, Yanan Ren, Li Wang, Sk. Kayum Alam, Rendong Yang, Alonso Guedes, Angela Craig, et al.

    Over half of all people diagnosed with cancer receive radiation therapy. Moderate to severe radiation dermatitis occurs in most human radiation patients, causing pain, aesthetic distress, and a negative impact on tumor control. No effective prevention or treatment for radiation dermatitis exists. The lack of well-characterized, clinically relevant animal models of human radiation dermatitis contributes to the absence of strategies to mitigate radiation dermatitis. Here, we establish and characterize a hairless SKH-1 mouse model of human radiation dermatitis by correlating temporal stages of clinical and pathological skin injury. We demonstrate that a single ionizing radiation treatment of 30 Gy using 6 MeV electrons induces severe clinical grade 3 peak toxicity at 12 days, defined by marked erythema, desquamation and partial ulceration, with resolution occurring by 25 days. Histopathology reveals that radiation-induced skin injury features temporally unique inflammatory changes. Upregulation of epidermal and dermal TGF-ß1 and COX-2 protein expression occurs at peak dermatitis, with sustained epidermal TGF-ß1 expression beyond resolution. Specific histopathological variables that remain substantially high at peak toxicity and early clinical resolution, including epidermal thickening, hyperkeratosis and dermal fibroplasia/fibrosis, serve as specific measurable parameters for in vivo interventional preclinical studies that seek to mitigate radiation-induced skin injury.


  • Open Access

    Longitudinal Neuropathological Consequences of Extracranial Radiation Therapy in Mice

    by Kimberly Demos-Davies, Jessica Lawrence, Jessica Coffey, Amy Morgan, Clara Ferreira, Luke H. Hoeppner, Davis Seelig

    Cancer-related cognitive impairment (CRCI) is a consequence of chemotherapy and extracranial radiation therapy (ECRT). Our prior work demonstrated gliosis in the brain following ECRT in SKH1 mice. The signals that induce gliosis were unclear. Right hindlimb skin from SKH1 mice was treated with 20 Gy or 30 Gy to induce subclinical or clinical dermatitis, respectively. Mice were euthanized at 6 h, 24 h, 5 days, 12 days, and 25 days post irradiation, and the brain, thoracic spinal cord, and skin were collected. The brains were harvested for spatial proteomics, immunohistochemistry, Nanostring nCounter® glial profiling, and neuroinflammation gene panels. The thoracic spinal cords were evaluated by immunohistochemistry. Radiation injury to the skin was evaluated by histology. The genes associated with neurotransmission, glial cell activation, innate immune signaling, cell signal transduction, and cancer were differentially expressed in the brains from mice treated with ECRT compared to the controls. Dose-dependent increases in neuroinflammatory-associated and neurodegenerative-disease-associated proteins were measured in the brains from ECRT-treated mice. Histologic changes in the ECRT-treated mice included acute dermatitis within the irradiated skin of the hindlimb and astrocyte activation within the thoracic spinal cord. Collectively, these findings highlight indirect neuronal transmission and glial cell activation in the pathogenesis of ECRT-related CRCI, providing possible signaling pathways for mitigation strategies.


  • Open Access

    Radiation dermatitis in the hairless mouse model mimics human radiation dermatitis

    by Jessica Lawrence, Davis Seelig, Kimberly Demos-Davies, Clara Ferreira, Yanan Ren, Li Wang, Sk. Kayum Alam, Rendong Yang, Alonso Guedes, Angela Craig, et al.

    Over half of all people diagnosed with cancer receive radiation therapy. Moderate to severe radiation dermatitis occurs in most human radiation patients, causing pain, aesthetic distress, and a negative impact on tumor control. No effective prevention or treatment for radiation dermatitis exists. The lack of well-characterized, clinically relevant animal models of human radiation dermatitis contributes to the absence of strategies to mitigate radiation dermatitis. Here, we establish and characterize a hairless SKH-1 mouse model of human radiation dermatitis by correlating temporal stages of clinical and pathological skin injury. We demonstrate that a single ionizing radiation treatment of 30 Gy using 6 MeV electrons induces severe clinical grade 3 peak toxicity at 12 days, defined by marked erythema, desquamation and partial ulceration, with resolution occurring by 25 days. Histopathology reveals that radiation-induced skin injury features temporally unique inflammatory changes. Upregulation of epidermal and dermal TGF-ß1 and COX-2 protein expression occurs at peak dermatitis, with sustained epidermal TGF-ß1 expression beyond resolution. Specific histopathological variables that remain substantially high at peak toxicity and early clinical resolution, including epidermal thickening, hyperkeratosis and dermal fibroplasia/fibrosis, serve as specific measurable parameters for in vivo interventional preclinical studies that seek to mitigate radiation-induced skin injury.